Form 4: Verve Therapeutics CFO Allison Dorval Reports Stock Transactions

Chief Financial Officer of Verve Therapeutics, Allison Dorval, reports the settlement of restricted stock units and a sale of shares to cover tax obligations.

Summary

• Allison Dorval, CFO of Verve Therapeutics, reported transactions involving the company's common stock.
• On April 1, 2025, 11,250 restricted stock units (RSUs) were settled, converting into common stock on a one-for-one basis.
• On April 2, 2025, 3,350 shares were sold at $4.15 per share to cover withholding tax liabilities related to the vesting of RSUs.
• Following these transactions, Dorval directly owns 13,280 shares of common stock and 33,750 restricted stock units.
• The sale of shares was executed according to a pre-arranged automatic sale plan adopted on March 20, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to equity compensation and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The vesting of RSUs indicates that Dorval is meeting the conditions of her equity compensation plan.
• The automatic sale plan helps to avoid any appearance of insider trading.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• Automatic sale plans are commonly used by executives to manage tax liabilities and avoid insider trading concerns.
• The vesting schedule of the RSUs (25% on April 1, 2025, and the remainder in equal annual installments until April 1, 2028) is a typical vesting structure for equity grants.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The sale of shares to cover tax obligations may slightly dilute existing shareholders' equity.

Key Dates

Keywords

Verve Therapeutics, Allison Dorval, CFO, Form 4, Stock Transactions, Restricted Stock Units, RSU, Common Stock, Beneficial Ownership, Automatic Sale Plan